颅底脑膜瘤治疗后长期健康相关生活质量与神经认知功能
这项多中心横断面研究纳入末次干预后≥5年的颅底脑膜瘤患者89例(中位随访9年),评估其健康相关生活质量(HRQOL)与神经认知功能。结果显示患者总体HRQOL与对照者及凸面脑膜瘤患者无显著差异,但后颅底患者HRQOL显著差于前/中颅底患者,首选放疗者部分HRQOL领域得分更低;肿瘤位置与治疗方式对神经认知功能无显著影响,但44%患者至少一个认知域存在缺陷。
要点
- 颅底脑膜瘤患者长期HRQOL与对照者及凸面脑膜瘤患者无显著差异。
- 后颅底患者HRQOL显著且临床相关地差于前/中颅底患者。
- 首选放疗者躯体疼痛与活力得分低于手术者;44%患者存在认知域缺陷。
核心结论
- 长期来看,颅底脑膜瘤患者HRQOL与神经认知功能较对照者及凸面脑膜瘤患者无显著更多后遗症。
- 后颅底患者HRQOL差于前/中颅底患者,首选放疗与更差HRQOL相关。
- 神经认知功能未受肿瘤位置或治疗方式显著影响。
研究设计与样本
- 多中心横断面研究,纳入末次肿瘤干预后5年及以上的颅底脑膜瘤患者。
- 使用SF-36与EORTC QLQ-BN20评估HRQOL,标准化神经心理评估测神经认知功能。
- 颅底脑膜瘤患者(n=89)与对照者(n=65)及凸面脑膜瘤患者(n=84)比较。
- 采用多变量与倾向评分回归分析校正混杂因素。
主要发现
- 颅底脑膜瘤患者(n=89)中位随访9年,总体HRQOL与对照者(n=65)及凸面脑膜瘤患者(n=84)无显著差异。
- 颅底脑膜瘤患者疾病特异性HRQOL较凸面脑膜瘤患者有统计学显著但非临床相关的更优。
- 前/中颅底患者(n=62)较后颅底患者(n=27)HRQOL显著且临床相关更优:角色生理(校正差值17.1,95%CI 0.2-34.0)、运动功能障碍(-10.1,95%CI -17.5至-2.7)、交流缺陷(-14.2,95%CI -22.7至-5.6)、双下肢无力(-10.1,95%CI -18.8至-1.5)。
- 首选放疗者较手术者在躯体疼痛(-33.0,95%CI -55.2至-10.9)与活力(-18.9,95%CI -33.7至-4.1)两领域HRQOL得分更低。
- 44%的颅底脑膜瘤患者至少一个认知域存在缺陷,但肿瘤位置与治疗方式未致神经认知功能显著差异。
临床怎么用
- 长期随访中应关注后颅底脑膜瘤患者的HRQOL,其较前/中颅底患者更差。
- 对首选放疗的颅底脑膜瘤患者,需评估躯体疼痛与活力等HRQOL领域。
- 尽管总体神经认知功能无显著差异,仍应筛查认知域缺陷(44%存在至少一域缺陷)。
局限性
- 为横断面研究,无法推断因果关系。
- 对照者为颅底脑膜瘤患者的非正式照护者,可能存在选择偏倚。
- 样本量有限,后颅底亚组仅27例,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with skull base meningioma (SBM) often require complex surgery around critical neurovascular structures, placing them at high risk of poor health-related quality of life (HRQOL) and possibly neurocognitive dysfunction. As the survival of meningioma patients is near normal, long-term neurocognitive and HRQOL outcomes are important to evaluate, including evaluation of the impact of specific tumor location and treatment modalities on these outcomes. METHODS: In this multicenter cross-sectional study including patients 5 years or more after their last tumor intervention, Short-Form Health Survey (SF-36) and European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BN20 questionnaires were used to assess generic and disease-specific HRQOL. Neurocognitive functioning was assessed with standardized neuropsychological assessment. SBM patient assessments were compared with those of 1) informal caregivers of SBM patients who served as controls and 2) convexity meningioma patients. In addition, the authors compared anterior/middle SBM patients with posterior SBM patients and anterior/middle and posterior SBM patients separately with controls. Multivariable and propensity score regression analyses were performed to correct for possible confounders. RESULTS: Patients with SBM (n = 89) with a median follow-up of 9 years after the last intervention did not significantly differ from controls (n = 65) or convexity meningioma patients (n = 84) on generic HRQOL assessment. Statistically significantly but not clinically relevantly better disease-specific HRQOL was found for SBM patients compared with convexity meningioma patients. Anterior/middle SBM patients (n = 62) had significantly and clinically relevantly better HRQOL in SF-36 and EORTC QLQ-BN20 scores than posterior SBM patients (n = 27): physical role functioning (corrected difference 17.1, 95% CI 0.2-34.0), motor dysfunction (-10.1, 95% CI -17.5 to -2.7), communication deficit (-14.2, 95% CI -22.7 to -5.6), and weakness in both legs (-10.1, 95% CI -18.8 to -1.5). SBM patients whose primary treatment was radiotherapy had lower HRQOL scores compared with SBM patients who underwent surgery on two domains: bodily pain (-33.0, 95% CI -55.2 to -10.9) and vitality (-18.9. 95% CI -33.7 to -4.1). Tumor location and treatment modality did not result in significant differences in neurocognitive functioning, although 44% of SBM patients had deficits in at least one domain. CONCLUSIONS: In the long term, SBM patients do not experience significantly more sequelae in HRQOL and neurocognitive functioning than do controls or patients with convexity meningioma. Patients with posterior SBM had poorer HRQOL than anterior/middle SBM patients, and primary treatment with radiotherapy was associated with worse HRQOL. Neurocognitive functioning was not affected by tumor location or treatment modality.
引用
- Fisher FL, Zamanipoor Najafabadi AH, van der Meer PB, et al. Long-term health-related quality of life and neurocognitive functioning after treatment in skull base meningioma patients. J Neurosurg. 2021. PMID: 34598137. doi:10.3171/2021.4.JNS203891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。